Effects of intrapartum zidovudine therapy on fetal heart rate parameters in women with human immunodeficiency virus infection

Fetal Diagnosis and Therapy

Volumn 16, Issue 6, 2001, Pages 413-416

  Blackwell, Sean C ^a,b   Sahai, Anjali ^a   Hassan, Sonia S ^a   Treadwell, Marjorie C ^a   Tomlinson, Mark W ^a   Jones, Theodore B ^a   Sorokin, Yoram ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUTZEL HOSPITAL   (United States)

Author keywords

Fetal heart rate; Human immunodeficiency virus infection; Zidovudine

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DEMOGRAPHY; FEMALE; GESTATIONAL AGE; HEART RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABOR; LABOR COMPLICATION; MATERNAL AGE; MECONIUM ASPIRATION; PREGNANCY; PRIORITY JOURNAL; UMBILICAL ARTERY; VIRUS INFECTION;

ADULT; FEMALE; GESTATIONAL AGE; HEART RATE, FETAL; HIV INFECTIONS; HUMANS; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 0034766494     PISSN: 10153837     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053950     Document Type: Article

References (25)

1. A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus
2. Reduction of maternal-infant transmission of human immunodeficiency virus type-1 with zidovudine
3. Obstetrical risk factors and the transmission of human immunodeficiency virus type 1 from mother to child
4. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV
5. Obstetrical factors and mother-to-child transmission of human immunodeficiency virus type 1: The French perinatal cohorts
6. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus
7. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis
8. Prevention of vertical HIV transmission: Additional protective effects of elective cesarean section and zidovudine prophylaxis
9. Perinatal HIV-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal cohort
10. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomized clinical trial
11. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: A meta-analysis of 15 prospective cohort studies
12. Electronic fetal heart rate monitoring: Research guidelines for interpretation
13. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers
14. Erratic zidovudine bioavailability in HIV seropositive patients
15. Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection
16. Transfer of zidovudine (ZDV) by human placenta
17. Transplacental transfer of zidovudine in the near-term pregnant baboon
18. Fetal cardiorespiratory and neurobehavioral response to zidovudine (AZT) in the baboon
19. Perinatal pharmacokinetics of zidovudine
20. Placental passage of azathiothymidine (ZDV) during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound
21. The pharmokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082)
22. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
23. AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content